Vista Pharma.

{
  "main_header": {
    "sid": 384463,
    "name": "Vista Pharma.",
    "stock_name": "Vista Pharma.",
    "full_name": "Vista Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/vista-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "7.74",
    "chg": 0.45,
    "chgp": "6.17%",
    "dir": 1,
    "prev_price": "7.29",
    "mcapval": "43.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524711,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE427C01021",
    "curr_date": "Apr 30",
    "curr_time": "",
    "bse_nse_vol": "6.08 k",
    "exc_status": "Active",
    "traded_date": "Apr 30, 2026",
    "traded_date_str": "2026 04 30",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vista-pharma-384463-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Vista Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vista-pharmaceuticals-ltd-is-rated-strong-sell-3963141",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/VistaPharmaceut_mojoScore_3963141.png",
        "date": "2026-04-26 10:10:13",
        "description": "Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 18 July 2024. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 26 April 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Vista Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vista-pharmaceuticals-ltd-is-rated-strong-sell-3947372",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/VistaPharmaceut_mojoScore_3947372.png",
        "date": "2026-04-15 10:10:17",
        "description": "Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics presented here reflect the company’s current position as of 15 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and overall outlook."
      },
      {
        "title": "Vista Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vista-pharmaceuticals-ltd-is-rated-strong-sell-3932612",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/VistaPharmaceut_mojoScore_3932612.png",
        "date": "2026-04-03 10:10:14",
        "description": "Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 18 Jul 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 03 April 2026, providing investors with the latest insights into its performance and prospects."
      },
      {
        "title": "Vista Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vista-pharmaceuticals-ltd-is-rated-strong-sell-3900257",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/VistaPharmaceut_mojoScore_3900257.png",
        "date": "2026-03-19 10:10:20",
        "description": "Vista Pharmaceuticals Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 19 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Vista Pharmaceuticals Ltd Stock Falls to 52-Week Low of Rs.5.71",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vista-pharmaceuticals-ltd-stock-falls-to-52-week-low-of-rs571-3879799",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/VistaPharmaceut_priceRelatedfactors_3879799.png",
        "date": "2026-03-09 11:27:42",
        "description": "Vista Pharmaceuticals Ltd’s stock declined to a fresh 52-week low of Rs.5.71 today, marking a significant downturn amid broader market weakness and company-specific headwinds. The stock underperformed its sector and has now reversed gains seen over the previous three sessions."
      },
      {
        "title": "Vista Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vista-pharmaceuticals-ltd-is-rated-strong-sell-3873130",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/VistaPharmaceut_mojoScore_3873130.png",
        "date": "2026-03-05 10:10:20",
        "description": "Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 March 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Vista Pharmaceuticals Ltd Stock Falls to 52-Week Low of Rs.6.05",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vista-pharmaceuticals-ltd-stock-falls-to-52-week-low-of-rs605-3864440",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/VistaPharmaceut_priceRelatedfactors_3864440.png",
        "date": "2026-03-02 10:57:17",
        "description": "Vista Pharmaceuticals Ltd’s stock touched a fresh 52-week low of Rs.6.05 today, marking a significant decline amid ongoing pressures in the Pharmaceuticals & Biotechnology sector. The stock has underperformed both its sector and broader market indices, reflecting persistent challenges in its financial and operational metrics."
      },
      {
        "title": "Vista Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vista-pharmaceuticals-ltd-is-rated-strong-sell-3845568",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VistaPharmaceut_mojoScore_3845568.png",
        "date": "2026-02-18 10:10:25",
        "description": "Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 18 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "Are Vista Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-vista-pharmaceuticals-ltd-latest-results-good-or-bad-3840314",
        "imagepath": "",
        "date": "2026-02-14 19:37:54",
        "description": "Vista Pharmaceuticals Ltd's latest financial results for Q3 FY26 indicate significant operational challenges. The company reported a net loss of ₹2.32 crores, which reflects a substantial year-on-year decline of 75.76%. This loss is accompanied by an operating margin of -123.97%, a deterioration from the previous year's margin of -58.98%, highlighting ongoing structural weaknesses in its operations.\n\nRevenue for the quarter stood at ₹2.42 crores, which, while showing a sequential improvement of 65.75% from ₹1.46 crores in Q2 FY26, still represents a 5.47% decline compared to ₹2.56 crores in Q3 FY25. This suggests that despite short-term recovery, the company is struggling to maintain consistent revenue growth over the longer term.\n\nThe nine-month performance for FY26 further illustrates the difficulties faced by Vista Pharmaceuticals, with total sales declining by 21.17% to ₹5.40 crores from ₹6.85 crores in..."
      }
    ],
    "total": 5715,
    "sid": "384463",
    "stock_news_url": "https://www.marketsmojo.com/news/vista-pharmaceuticals-384463"
  },
  "announcements": [
    {
      "caption": "Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2",
      "datetime": "29-Apr-2026",
      "details": "<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Vista Pharmaceuticals Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24239TG1991PLC012264</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2025-26 2026-27</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2024-25 2025-26</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Barka Jain</td></tr><tr><td>Designation :-</td><td>Company Secretary compliance Officer</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Suneel pachipala</td></tr> <tr><td>Designation : -</td><td>CFO</td></tr></table><div> <br/> Date: 29/04/2026<br/><br/></div>",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "14-Apr-2026",
      "details": "Compliance - certificate under Reg. 74(5) of SEBI (DP) Regulations 2018",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "27-Mar-2026",
      "details": "Closure of Trading Window",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Vista Pharmaceuticals Ltd is Rated Strong Sell

2026-04-26 10:10:13

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 18 July 2024. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 26 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Vista Pharmaceuticals Ltd is Rated Strong Sell

2026-04-15 10:10:17

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics presented here reflect the company’s current position as of 15 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and overall outlook.

Read full news article

Vista Pharmaceuticals Ltd is Rated Strong Sell

2026-04-03 10:10:14

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 18 Jul 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 03 April 2026, providing investors with the latest insights into its performance and prospects.

Read full news article

Vista Pharmaceuticals Ltd is Rated Strong Sell

2026-03-19 10:10:20

Vista Pharmaceuticals Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 19 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Vista Pharmaceuticals Ltd Stock Falls to 52-Week Low of Rs.5.71

2026-03-09 11:27:42

Vista Pharmaceuticals Ltd’s stock declined to a fresh 52-week low of Rs.5.71 today, marking a significant downturn amid broader market weakness and company-specific headwinds. The stock underperformed its sector and has now reversed gains seen over the previous three sessions.

Read full news article

Vista Pharmaceuticals Ltd is Rated Strong Sell

2026-03-05 10:10:20

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 March 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Vista Pharmaceuticals Ltd Stock Falls to 52-Week Low of Rs.6.05

2026-03-02 10:57:17

Vista Pharmaceuticals Ltd’s stock touched a fresh 52-week low of Rs.6.05 today, marking a significant decline amid ongoing pressures in the Pharmaceuticals & Biotechnology sector. The stock has underperformed both its sector and broader market indices, reflecting persistent challenges in its financial and operational metrics.

Read full news article

Vista Pharmaceuticals Ltd is Rated Strong Sell

2026-02-18 10:10:25

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 18 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

Are Vista Pharmaceuticals Ltd latest results good or bad?

2026-02-14 19:37:54

Vista Pharmaceuticals Ltd's latest financial results for Q3 FY26 indicate significant operational challenges. The company reported a net loss of ₹2.32 crores, which reflects a substantial year-on-year decline of 75.76%. This loss is accompanied by an operating margin of -123.97%, a deterioration from the previous year's margin of -58.98%, highlighting ongoing structural weaknesses in its operations. Revenue for the quarter stood at ₹2.42 crores, which, while showing a sequential improvement of 65.75% from ₹1.46 crores in Q2 FY26, still represents a 5.47% decline compared to ₹2.56 crores in Q3 FY25. This suggests that despite short-term recovery, the company is struggling to maintain consistent revenue growth over the longer term. The nine-month performance for FY26 further illustrates the difficulties faced by Vista Pharmaceuticals, with total sales declining by 21.17% to ₹5.40 crores from ₹6.85 crores in...

Read full news article

View All News